Breaking AI & Tech News Analyzed

The conflict between Iran, the US, and Israel has taken a severe turn with a series of coordinated attacks on Iranian universities and infrastructure. A research center at Shahid Beheshti University in Tehran was recently bombed, leaving it in ruins. This attack is part of a larger pattern of civilian sites being targeted by the US and Israel. Over 30 universities have been impacted since the start of the war on February 28, according to Hossein Simaei Saraf, the Iranian minister of science, research, and technology. The attacks have not only damaged educational facilities but also research centers, including those working on domestically made satellites and infectious diseases. The Pasteur Institute in Tehran, a renowned center for vaccine development and biological products, was also attacked, sustaining significant damage and disrupting health services. The World Health Organization (WHO) confirmed the damage and noted that no casualties were reported. In addition to educational and healthcare facilities, over 20 healthcare facilities have been targeted since March 1, according to WHO Director-General Tedros Adhanom Ghebreyesus. The attacks have also affected schools, houses, and businesses, resulting in over 2,000 deaths and widespread destruction. The economic sector has not been spared, with petrochemical and steel factories being destroyed in recent bombardments. The US and Israel have also targeted critical infrastructure, including power plants and water desalination plants, which are civilian targets protected under international law. The Iranian government and the Islamic Revolutionary Guard Corps (IRGC) have vowed to retaliate and escalate attacks across the region. The situation has drawn international condemnation, with over 100 US legal experts expressing concerns about potential war crimes and violations of international humanitarian law.

Jeffrey Stephen Wigand, a biochemist who helped reveal how tobacco companies targeted children and hid the addictive nature of cigarettes, has been drawing parallels between the tobacco industry and social media companies. Wigand, who played a crucial role in the landmark tobacco trials of the 1990s, believes that social media companies have similarly designed their products to be addictive, particularly targeting children.The recent verdict in a major social media trial, which found Meta and YouTube liable for their role in creating addictive products, has strengthened comparisons to the legal crackdown on big tobacco. Wigand sees it as a similar situation, where companies prioritize profits over people's well-being. He notes that both industries use advertisements to target children, with social media companies using data to create addictive algorithms.Wigand's experience in the tobacco industry informs his perspective on social media. He was hired by Brown & Williamson (B&W;) in 1989 to develop a safer cigarette but was fired after raising concerns about carcinogenic substances in cigarettes. He then publicly declared that the tobacco industry was a 'nicotine delivery business' and helped the federal government in its investigations.Wigand believes that social media companies, like tobacco companies, intentionally addict people, especially children, to generate revenue. He emphasizes that brain development in children makes them vulnerable to addiction, and that social media companies exploit this vulnerability.The tobacco industry faced significant reforms and financial penalties following Wigand's whistleblowing. He hopes that similar actions will be taken against social media companies, including putting guardrails on access for children and holding companies accountable for their role in creating harm. Wigand's message to tech workers considering becoming whistleblowers is to carefully weigh the personal costs and prepare for the challenges that come with speaking out.

The UK government has announced that it will not pursue a ban on foie gras imports and will not restrict fur imports, citing the need to prioritize trade agreements with the EU. This decision reverses a previous commitment to restrict the import of these products, which are often associated with animal cruelty.The move has been criticized by animal welfare charities, who argue that the UK's high animal welfare standards should not be compromised for the sake of trade agreements. The RSPCA and other organizations have expressed disappointment and concern about the impact on animal welfare.The UK had previously banned fur farming in 2000 and the production of foie gras in 2006, but imports of these products have continued. The EU has made it clear that it will not allow member states to ban each other's products on animal welfare grounds, which has limited the UK's ability to restrict imports.The decision is seen as a significant concession to the EU as the UK seeks to secure a trade deal. The government has stated that it is prioritizing economic growth and has set up a working group to examine the fur industry.Animal welfare charities and some businesses are urging the government to reconsider its decision and maintain its commitment to banning these products. Some restaurants and shops have already removed foie gras from their menus and shelves, citing concerns about animal welfare.

When Kayleigh Davies, a seasoned valuer at the auction platform Auctionet, examined the base of a vase marketed as a genuine Lalique piece, she immediately recognised the deception. The word “Lalique” had been crudely engraved onto the bottom, a trick the seller hoped would inflate the price.Davies rejected the item, noting that without the fraudulent engraving it would have been a saleable piece. Her experience underscores a growing problem: traditional antique scams are being amplified by the reach of internet marketplaces.Typical red flagsFraudsters often disguise flaws—such as restored cracks or repainted toy cars—while claiming pristine condition. Even high‑value items like original‑packaged Star Wars figures can be misrepresented by placing cheap replicas in authentic‑looking boxes.Other warning signs include unexplained scuffs on glassware, suspiciously perfect finishes on aged objects, and a lack of clear provenance for autographs. Davies advises buyers to ask probing questions; a dishonest seller is likely to become evasive or refuse further details.Electrical collectibles, such as vintage lamps, pose additional hazards, as faulty wiring can lead to fire risks.Consumer safeguardsPlatforms like eBay enforce strict policies against counterfeit goods and offer a “money‑back guarantee” that protects purchasers when items do not match their listings.In the UK, Citizens Advice confirms that buyers have a legal right to a refund for fake products. If a seller refuses, shoppers can:Initiate a chargeback through their bank if they paid by debit card or used a credit card for purchases under £100.File a Section 75 claim for credit‑card purchases over £100, shifting liability to the card issuer.Suspected fraud can also be reported to the national Report Fraud centre, and to local Trading Standards via Citizens Advice.By staying vigilant, demanding documentation, and leveraging consumer‑rights mechanisms, buyers can reduce the risk of falling victim to counterfeit antiques and collectibles.

In a viral trend on TikTok, Londoners are reviewing upmarket bakeries and cafes in their neighborhoods, sparking conversations about gentrification and the changing face of local businesses.Moses Combe, a 21-year-old from north London, started a series of videos called the 'Endz Department for Research', where he reviews upscale cafes that he wouldn't normally visit. His goal is to investigate the changes happening in his own backyard. Combe's review of Jolene, a bakery he describes as 'giving Gail's Pro Max', comes to £14.20. He enjoys the sausage roll, saying 'They did not skimp out with that sausage, bro.'Combe isn't alone in his reviews. Kobi Coker, a 27-year-old comedian and educator, also reviews 'gentrified' spaces. He says his videos exploring these areas weren't initially intentional but were sparked by noticing new, upmarket establishments opening up on his road during his daily commute. Coker has reviewed the Dusty Knuckle bakery, Jolene, Gail's, and Pret, often joking about his experiences.The trend has led to discussions about gentrification and its impact on local businesses. Coker notes that while some new businesses bring new ideas, the problem is that long-time residents 'aren't necessarily able to participate in it.' Matthew Roberts, operations manager at Jolene, welcomes the attention, saying it's 'all very positive' and that they want to 'welcome absolutely everybody.'Other reviewers, like Daniel Poon, a 27-year-old content creator, review mainstream chains when they release products inspired by other cuisines. He reviewed Pret's ube drink, saying it didn't feel authentic to the original Filipino flavor. Poon appreciates chains' efforts to branch out and try new things, but also values diversity and trying different cuisines.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.

The UK is facing a potential rebranding of its beloved breakfast spread, marmalade, due to new EU rules. The proposed changes are part of a planned food deal with the EU, which would require the UK to align with the bloc's naming rules for food products.Under the new rules, marmalades may need to be relabelled to specify the type of fruit used, such as 'citrus marmalade'. However, the government has clarified that 'orange marmalade' will still be allowed and that jars on UK shelves will remain unchanged.The Conservative former home secretary, Priti Patel, has accused Labour of 'attacking the great British marmalade', claiming that the prime minister is 'desperate to fit in with his EU pals and unpick Brexit'. However, the government spokesperson has denied this, stating that the deal simply supports trade by cutting unnecessary red tape.The UK is being asked to align with regulations already in force within the EU, which allow all conserves to be marketed as marmalades as long as the type of fruit is specified. The rules were relaxed in 2004 to allow fruit-based spreads to be referred to as marmalades in certain European countries.A government source pointed out that marmalade on UK supermarket shelves is already usually labelled as 'orange marmalade', which they suggested is in compliance with the EU rules. The government has assured that the agreement supports exporters while fully preserving the UK's ability to shape food rules in the national interest.

The current global landscape is marked by uncertainty, with Donald Trump's policies contributing to a sense of instability. As the world grapples with the implications of the Iran war, including a potential global shortage of jet fuel, the UK is reevaluating its relationships. Keir Starmer, leader of the Labour Party, has argued that a closer partnership with Europe is in Britain's national interest. This stance is echoed by Rachel Reeves, highlighting the need for the UK to strengthen its ties with the EU to mitigate the risks of a global economic crisis. The article notes that 63% of Britons would vote to rejoin the EU if a referendum were held today, according to recent YouGov polling. This sentiment is reflected in the growing popularity of a youth mobility scheme that would allow young people to work and study abroad, a proposal that has gained traction even among Leave voters. Starmer's ally, Nick Thomas-Symonds, has been negotiating a deal that would align with EU rules on food and drink, potentially leading to the relabelling of certain products like marmalade. While challenges remain, including competitive trade interests, the article suggests that Europe is choosing unity in the face of crisis. The author, Gaby Hinsliff, argues that Britain has learned from its past mistakes and is now seeking to build a new relationship with the EU at speed. While rejoining the EU is not imminent, the will and political courage are needed to seize this second chance.